MedTrace Logo

CINC424A2X01B Rollover Protocol

NCT02386800 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 279

Last updated 2026-03-16

No results posted yet for this study

Summary

This is a long term safety study for patients that have been treated with either ruxolitinib or a combination of ruxolitinib with panobinostat, on a Novartis or Incyte sponsored study, who have been judged by the study Investigator to benefit from ongoing treatment.

Conditions

Interventions

DRUG

ruxolitinib

ruxolitinib tablets or pediatric oral solution - participants continue ruxolitinib as they received in parent study

DRUG

panobinostat

panobinostat capsules - participants to continue receiving panobinostat in combination with ruxolitinib as per the parent study

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharma, A.G · Novartis Pharma, A.G.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Month
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-05
Primary Completion
2027-09-16
Completion
2027-09-16

Countries

  • Australia
  • Belgium
  • Bulgaria
  • Canada
  • Chile
  • China
  • France
  • Germany
  • Greece
  • Hungary
  • India
  • Israel
  • Italy
  • Japan
  • Lebanon
  • Mexico
  • Poland
  • Portugal
  • Russia
  • South Africa
  • South Korea
  • Spain
  • Sweden
  • Thailand
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02386800 on ClinicalTrials.gov